arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

HARVARD BIOSCIENCE INC

HBIO
$6.43 ▲ +0.24 (+3.88%) at close
Industrials ·Laboratory Analytical Instruments ·USLaboratory Analytical Instruments
67 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
19
Health
Poor
Bearish
auto_awesome

Analytical Summary

HARVARD BIOSCIENCE INC faces fundamental challenges with weakness in Profit Margin (%) and Debt to Equity. The fundamentals warrant careful consideration of downside risks.

Market Cap $28.8M
Dividend Yield
Revenue Growth -4.7%
Op. Margin -5.7%
ROIC -2.6%
FCF / Share $-0.24
Trailing P/E
Price / Book 28.6x
FCF Yield
Debt / Equity 3.60
info Valuation on last close. End-of-day price, Aug 7, 2026.

67-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$20.75M
↓ -4.7%
Net Income Profit after all expenses
$-3.42M
↑ +93.2%
Operating Margin Operating profit as % of sales
-5.7%
↓ -178.5% 5th
FCF / Share Free cash flow per share
$-0.24
↓ -1335.8%
Long-Term Debt Long-term obligations
$36.21M
↑ +1.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
19
Financial Health
18
Cash Quality
19

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 67 quarters